Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Kairos Pharma, LTD. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 2 | 5 | +3 |
| Shares | 45.3K | 406.6K | +361.3K (+797.2%) |
| Value | $70.0K | $618.3K | +$548.3K (+783.2%) |
New holders (4)
Institutions that held Kairos Pharma, LTD. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Umb Bank N A | 371,115 | $564.1K | 0.01% |
| Citadel Advisors LLC | 10,969 | $16.7K | 0.00% |
| UBS Group AG | 10,845 | $16.5K | 0.00% |
| Bank of America Corp | 13 | $20 | 0.00% |
Sold out (1)
Institutions that held Kairos Pharma, LTD. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| HRT Financial LP | 12,609 | $19.0K |